Second Quarter 2023 Report
July 30, 2023
Premium Version of OneTest Set to Lauch
In August we expect to launch OneTest Premium, a version of our multi-cancer early detection (MCED) blood test with 5 additional biomarkers for enhanced sensitivity and specificity. This product, which will be offered to our growing base of OneTest customers, was developed by Seoul based BioInfra who has offered a similar test in Korea for more than 5 years. (20/20 is BioInfra's exclusive U.S. licensee.) Information on test accuracy may be viewed here. Recently BioInfra analyzed the results from over 42,000 of their tested individuals with outcomes from the Korean cancer registry and found an excellent correlation between those with high test signal and subsequent cancer diagnosis.
20/20 Seeking to Introduce Lung Cancer Testing in China in Partnership with Ping An Testing Centers & MD Anderson
More than one-third of the world's cigarettes are smoked in China and over 50% of all adult males in that country are either current or former tobacco smokers. These statistics suggest that China would be an important market for the lung cancer test developed at the MD Anderson cancer center (MDACC) that our company seeks to introduce later this year.

In June 20/20's COO Jiming Zhou, Ph.D. visited China, accompanied by Ed Ostrin, MD, a pulmonary medical specialist from the MDACC. The delegation met with the leadership of the Ping An Testing Center which currently provides screening tests to millions of current and former smokers throughout China every year. (Ping An is a large shareholder of 20/20.) The Ping An Testing Center estimated a potential demand of up to 500,000 tests per year from their customer base alone.

Information about the MD Anderson lung cancer test can be gleaned from this video, blog, or their latest peer-reviewed publication.
MCED 1H'23 Sales Double Over Prior Year
For the 6-month period ending June 30, OneTest sales totaled just under $400,000, marking a more than 100% increase over the same period in 2022. More than $1 million in sales of this MCED are anticipated to occur in the second half of this year, triple the volume over this same period last year.
New Markets for Multi-Cancer Blood Test
Since the launch of OneTest the majority of the consumers were in occupations with higher-than-average risks of certain cancers (e.g., firefighters). But during the first half of 2023 we have seen two trends that suggest broader markers.  The number of individual consumers ordering the test online increased to over 500 during the first half of this year compared to just over 300 during the second half of 2022.  

Additionally, medical professionals such as those in primary care, integrative medicine, functional medicine, occupational health and other specialties are now seeking to integrate OneTest into their medical practices. One notable example is Fountain Life, a proactive healthcare services company co-founded by best-selling authors Tony Robbins and Peter Diamadis, MD. In June we signed an agreement with Fountain Life which has 3,000 customers to date with rapid growth.
Third U.S. Patent to Issue Covering Lung Cancer Blood Test
In June, the company received a Notice of Allowance from the U.S. Patent & Trademark Office with respect to a pending patent application titled "Methods and Algorithms for Aiding in the Detection of Cancer" which covers the use of several of the biomarkers in OneTest (CEA, CA 125, Cyfra) when used in certain lung cancer screening program. The patent, which is set to issue on August 22, is the third directed to lung cancer screening methods that have recently been demonstrated to reduce death rates.  
Former LabCorp Executive to Join 20/20 Board
Prasanth Reddy, MD, who until recently served as a Senior Vice President and Head of Oncology for LabCorp, has agreed to join 20/20's Board of Directors. Triple-board certified in internal medicine, medical oncology and hematology, Dr. Reddy is a Lt. Col. in the Air Force Reserves. He recently declared his candidacy to run for Congress in Kansas' 3rd District.

Our previous Quarterly Reports and Press Releases may be downloaded here:
Financial Reports
In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those reports may be accessed by entering "20/20 GeneSystems, Inc." at or by contacting [email protected]

Forward Looking Statements
This quarterly report to shareholders contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our offering statements and reports under the heading “Risk Factors” as filed with the SEC. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this quarterly report to shareholders speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events or otherwise.